Inozyme Pharma, Inc.

INZY · NASDAQ
Analyze with AI
3/31/2025
12/31/2024
9/30/2024
6/30/2024
Assets
Cash & Equivalents$25,846$21,081$24,575$15,233
Short-Term Investments$58,930$92,006$107,033$129,290
Receivables$0$467$0$0
Inventory$0$0$0$0
Other Curr. Assets$8,861$7,122$9,329$8,439
Total Curr. Assets$93,637$120,676$140,937$152,962
Property Plant & Equip (Net)$1,018$1,346$1,655$1,981
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$311
Tax Assets$0$0$0$0
Other NC Assets$509$1,160$769$458
Total NC Assets$1,527$2,506$2,424$2,750
Other Assets$0$0$0$0
Total Assets$95,164$123,182$143,361$155,712
Liabilities
Payables$3,670$2,530$2,210$3,527
Short-Term Debt$26,369$15,415$5,548$1,918
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$12,742$15,953$10,586$10,096
Total Curr. Liab.$42,781$33,898$18,344$15,541
LT Debt$20,585$31,458$42,229$45,751
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$20,585$31,458$42,229$45,751
Other Liabilities$0$0$0$0
Cap. Leases$669$913$1,149$1,378
Total Liabilities$63,366$65,356$60,573$61,292
Equity
Pref Stock$0$0$0$0
Common Stock$6$6$6$6
Retained Earnings-$415,993-$387,954-$360,880-$336,310
AOCI-$5$69$186-$103
Other Equity$447,790$445,705$443,476$430,827
Total Equity$31,798$57,826$82,788$94,420
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$95,164$123,182$143,361$155,712
Net Debt$21,108$25,792$23,202$32,436